A real-world cohort study reveals disparities in biomarker testing and survival in thoracic malignancy with interstitial pneumonia, suggesting ongoing challenges in treatment planning.
Key Points
Evaluate the real-world effects of interstitial pneumonia on biomarker testing and survival outcomes in thoracic malignancy patients receiving systemic therapy.
Analyzed data from 1247 thoracic malignancy patients at a tertiary teaching hospital between 2016 and 2023.
Compared biomarker testing rates and survival outcomes between patients with and without interstitial pneumonia.
Calculated hazard ratios to assess the impact of interstitial pneumonia on survival outcomes.
Only 7.5% of patients had comorbid interstitial pneumonia (98 out of 1247).
PD-L1 testing rates were significantly lower in IP patients (63.3%) compared to non-IP patients (75.1%).
Immune checkpoint inhibitor therapy was utilized in 12.2% of IP patients versus 29.3% in non-IP patients.
Comorbid IP was associated with worse survival, with a hazard ratio of 1.789 (p < 0.001).
No survival improvement was observed in IP patients after 2020, despite gains in non-IP patients.